Composition, form of production and packaging
The solution for the / m introduction is transparent, light yellow in color.
1 ml
vaccine for the prevention of Pseudomonas infection 1 dose, including:
Immunotype antigens 1 0.125 ml
Immunotype antigens 2 0.125 ml
Immunotype antigens 3 0.125 ml
Immunotype antigens 4 0.125 ml
Immunotype antigens 5 0.125 ml
Immunotype antigens 6 0.125 ml
Immunotype antigens 7 0.125 ml
Immunotype antigens 3.7 0.125 ml
Excipients: phenol 2-4 mg.
1 ml (1 dose) - ampoules glass (5) - packings of cellular contour plastic (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
PHARMACHOLOGIC EFFECT
When using Pseudovac vaccine for preventive or curative purposes, the drug stimulates active immunity, which is manifested by an increase in the level of antibodies to Pseudomonas aeruginosa in the blood plasma. The introduction of the vaccine immediately after injury is associated with a reduction in the risk of bacteremia and sepsis caused by Pseudomonas aeruginosa.
INDICATIONS
- for the purpose of forming active immunity to Pseudomonas aeruginosa infections and can be used in any conditions accompanied by an increased risk of Pseudomonas aeruginosa or sepsis, especially in patients with extensive burns;
- for prophylactic purposes with the purpose of forming active immunity to Pseudomonas infections with prolonged hospitalization, intubation, artificial ventilation, catheterization, recurrent infections, various types of wounds, including postoperative ones;
- for medicinal purposes in patients with laboratory-proven Pseudomonas aeruginosa infections, such as pneumonia, lower respiratory tract infections, urinary tract infections and others, to enhance specific immunity and reduce the risk of bacteremia and sepsis.
DOSING MODE
To enter intramuscularly. Do not administer intravenously.
In children from 1 month and adults, Psevdovac vaccine for therapeutic and prophylactic purposes should be used according to the protocol below:
Day Vaccine volume
1 0.2 ml
4 0.4 ml
6 0.6 ml
8 0.8 ml
10 1.0 ml
When immunizing burn patients, the vaccine is administered as early as possible (1-3 days after injury), strictly following the above scheme.
With the development of adverse reactions of a local or systemic nature, it is allowed to increase the interval between administration of the drug or to re-administer the vaccine at the same dose with the next injection, the final dose of the drug, however, should be 1.0 ml. Exceeding the final dose (1.0 ml) is not allowed.
SIDE EFFECT
In rare cases, the following adverse reactions are possible:
- Local reactions: redness, painful swelling.
- Common reactions: headache, fever, fatigue.
Symptoms usually go through 24-48 hours.
CONTRAINDICATIONS
- Acute infections with fever not caused by bacteria Pseudomonas aeruginosa;
- exacerbation of a chronic disease. In these cases, the vaccination is performed after remission has been achieved;
- Pregnancy and lactation;
- allergic reactions to the previous administration of the vaccine or hypersensitivity to the components of the drug /
Light infections are not a contraindication for the use of the vaccine.
PREGNANCY AND LACTATION
Contraindicated in pregnancy and lactation.
APPLICATION FOR CHILDREN
Applied in children from 1 month.
SPECIAL INSTRUCTIONS
Before using the vaccine, it is necessary to conduct a medical examination of the patient and to analyze the history of the patient, as well as information on vaccinations conducted earlier.
Before each injection of the vaccine, the patient should be asked whether there were any unpleasant symptoms after the previous administration of the drug.
Such a technique allows assessing the risk of the side effects of immunization.
In connection with the danger of developing an anaphylactic shock associated with the use of biological agents, the introduction of a vaccine should prepare the necessary set of anti-shock drugs.
After the injection, the doctor should monitor the patient for 30 minutes.
Impact on the ability to drive vehicles and manage mechanisms
So far, there is no data.
OVERDOSE
So far, there is no data.
DRUG INTERACTION
So far, there is no data.
TERMS OF RELEASE FROM PHARMACY
For treatment and prevention institutions.
TERMS AND CONDITIONS OF STORAGE
In the dark place at a temperature of 2 to 8 В° C. Do not freeze. Keep out of the reach of children.
Shelf life - 1.5 years.
